immatics Announces Publication of IMA901 Cancer Vaccine Data in Nature Medicine: Immune Response Associates With Longer Survival

immatics Announces Publication of IMA901 Cancer Vaccine Data in Nature Medicine: Immune Response Associates With Longer Survival PR Newswire TUEBINGEN, Germany, July 29, 2012 TUEBINGEN, Germany, July 29, 2012 /PRNewswire/ -- Paper highlights clinical and immunological activity of IMA901 in renal cell carcinoma (RCC) IMA901 is currently being evaluated in a pivotal phase 3 randomized study in patients with RCC immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine. The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to more than one of the peptides in IMA901, the first multi-peptide therapeutic cancer vaccine for RCC. IMA901 consists of 10 tumor-associated peptides (TUMAPs) confirmed to be naturally presented on tumor cells in patients with renal cell carcinoma (RCC). immatics identified, selected and validated the peptides in IMA901 using its TMproprietary XPRESIDENT platform, which has enabled a uniquely rational approach to cancer vaccine development. The Nature Medicine paper reports the findings of two clinical trials with IMA901 in RCC patients.